Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic

N. Araújo1,2, A. Costa1,2, L. Lopes-Conceição1, A. Ferreira3, F. Carneiro3, J. Oliveira3, I. Braga3, S. Morais1,2, L. Pacheco-Figueiredo4, L. Ruano1,2, V. T. Cruz1,2, S. Pereira1,2,3 & N. Lunet1,2,5*

1EPIUnit – Instituto de Saúde Pública, Universidade do Porto, Porto; 2Laboratório Para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto; 3Instituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida, Porto; 4Instituto de Investigação em Ciências da Vida e Saúde, Escola de Medicina da Universidade do Minho, Campus de Gualtar, Braga; 5Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, Alameda Professor Hernâní Monteiro, Porto, Portugal

Available online 7 March 2022

Background: Androgen-deprivation therapy (ADT) has been associated with cognitive decline, but results are conflicting. This study describes changes in cognitive performance in patients with prostate cancer, according to ADT, during the first year after prostate cancer diagnosis.

Patients and methods: Patients with prostate cancer treated at the Portuguese Institute of Oncology of Porto (n = 366) were evaluated with the Montreal Cognitive Assessment (MoCA), before treatment and after 1 year. All baseline evaluations were performed before the coronavirus disease 2019 (COVID-19) pandemic and 69.7% of the 1-year assessments were completed after the first lockdown. Cognitive decline was defined as the decrease in MoCA from baseline to the 1-year evaluation below 1.5 standard deviations of the distribution of changes in the whole cohort. Participants scoring below age- and education-specific normative reference values in the MoCA were considered to have cognitive impairment. Age- and education-adjusted odds ratios (aORs) were computed for the association between ADT and cognitive outcomes.

Results: Mean MoCA scores increased from baseline to the 1-year evaluation (22.3 versus 22.8, \(P < 0.001\)). Cognitive decline was more frequent in the ADT group, and even more after the onset of the COVID-19 pandemic (aOR 6.81 versus 1.93, \(P\) for interaction = 0.233). The 1-year cumulative incidence of cognitive impairment was 6.9% (9.1% before and 3.7% after the pandemic onset), which was higher among patients receiving ADT, but only after the pandemic (aOR 5.53 versus 0.49, \(P\) for interaction = 0.044).

Conclusions: ADT was associated with worse cognitive performance of patients with prostate cancer, mostly among those evaluated after the first COVID-19 lockdown.

Key words: prostate cancer, neurocognitive disorders, longitudinal studies, hormones, hormone substitutes, hormone antagonists/analogues and derivatives, COVID-19, complications

INTRODUCTION

With nearly 5 million 5-year prevalent cases estimated in 2020, patients with prostate cancer represent the largest population of male cancer survivors worldwide.1 Nearly half of these patients may have been submitted to Androgen-deprivation therapy (ADT) during the course of the disease.2 ADT is used in clinically localized prostate cancer to complement radical radiotherapy; in regional disease (lymph nodes affected), alone or associated with radiotherapy; in metastatic disease; and in persistent or recurrent disease after radical prostatectomy or radiotherapy.3 However, ADT has been associated with several adverse effects, including cognitive decline and dementia. Most studies on cognitive decline were small and yielded heterogeneous results, and have been summarized in a meta-analysis that showed an association between ADT and a decline in visuomotor tasks.4 More recently, retrospective studies based on large health records, claims, and other administrative electronic databases found conflicting results on the association between ADT and dementia.5-9 In the available prospective studies, an accurate assessment of the potential effect of ADT on cognitive performance was limited by instrument...
variability, small sample sizes, and short follow-up duration. Moreover, cognitive outcomes were essentially based on the variation in cognitive performance from a baseline to a follow-up evaluation, and there is no study reporting the incidence of cognitive impairment, defined as a performance below the expected, accounting for age and education.

Therefore, in a cohort evaluated before treatments for prostate cancer and after 1 year, this study aimed to compare the variation in cognitive performance scores and the incidence of cognitive impairment between patients treated with ADT and those who received treatments without ADT. The follow-up period comprises the pre- and post-first lockdown periods due to the coronavirus disease 2019 (COVID-19) pandemic. Because the restrictions to daily life activities imposed to control the pandemic may have contributed to less cognitive stimulation and worsening of cognitive impairment, data were also analysed taking into account the possible effects of the pandemic on cognitive performance of patients with prostate cancer.

**METHODS**

The NEON-PC prospective cohort study was developed at the Portuguese Institute of Oncology of Porto (IPO-Porto), and has been described in detail elsewhere. In brief, between February 2018 and March 2020, patients recently diagnosed with prostate cancer and proposed for any treatment, including active surveillance, and those with a disease recurrence to be treated with ADT, were considered eligible and consecutively recruited. Illiterate patients and non-Portuguese native speakers were excluded, as well as those with a previous history of chemotherapy, radiotherapy, or ADT, and those with a neurologic or psychiatric condition impairing cognitive performance diagnosed before prostate cancer. Patients were recruited at the end of the multidisciplinary tumour board meeting when the different available options to treat their cancer were proposed.

A total of 486 participants were evaluated at baseline and 366 (75.3%) at the 1-year evaluation. All baseline evaluations were concluded before the COVID-19 pandemic and 69.7% of the 1-year assessments were performed after the first lockdown due to the pandemic. A total of 120 participants were not evaluated at 1 year because their evaluation was postponed due to the pandemic (n = 66), or were lost to follow-up, due to refusal to participate (n = 36), follow-up at another hospital (n = 5), severe hypoacusia precluding the 1-year evaluation (n = 1), ADT refusal (n = 1), brachytherapy not performed because of diagnosis and treatment with chemotherapy for another primary tumour (n = 2), or death (n = 7). Those who did not perform the 1-year evaluation had a lower educational level [education in years, median [percentile 25-percentile 75 (P25-P75)]: 4 (4-8) versus 5 (4-10); P = 0.013] and had a lower baseline score in the Montreal Cognitive Assessment (MoCA) [mean, standard deviation (SD): 20.6 (4.12) versus 22.4 (3.69); P < 0.001]. Participants evaluated at 1 year received treatments including ADT more frequently and underwent brachytherapy less frequently (P = 0.006; Table 1).

At baseline and at the 1-year evaluation, the cognitive performance of participants was evaluated with the MoCA. This cognitive test was developed to detect mild cognitive impairment, and demonstrated good sensitivity and specificity. It assesses eight cognitive domains with 12 tasks and its score ranges from 0 to 30, with lower scores indicating worse cognitive performance. Participants completed the Hospital Anxiety and Depression Scale (HADS), and anxiety and depression subscores ≥11 out of 21 were considered indicative of clinically significant anxiety and depression symptoms, respectively.

Clinical information regarding prognostic cancer stage group and treatments performed was retrieved from medical files. Prognostic cancer stage group, based on the tumour, nodes, metastases classification, Gleason grade, and prostate-specific antigen, was defined according to the AJCC (American Joint Committee on Cancer) TNM system, eighth edition. Gleason scores were grouped into Gleason grades according to the International Society of Urological Pathology. This is an observational study and participants were treated according to usual practice at IPO-Porto. First-line drugs used in ADT included goserelin with or without bicalutamide or, in a few cases, degarelix; second-line treatment included abiraterone acetate and enzalutamide. Most patients admitted to IPO-Porto with symptomatic metastatic prostate cancer were prescribed 150 mg bicalutamide per day at the first consultation until the

**Table 1. Characteristics of the participants evaluated at 1 year**

| Participation at 1 year | P value |
|-------------------------|---------|
| **No**                  |         |
| N = 120                 |         |
| **Yes**                 |         |
| N = 366                 |         |

| Age (years), mean (SD) |         |
|------------------------|---------|
| 68.1 (6.95)            | 67.8 (7.27) |
| 0.736                  |         |

| Education (years), median (P25-P75) |         |
|-------------------------------------|---------|
| 4 (4-8)                             | 5 (4-10) |
| 0.013                               |         |

| MoCa, mean (SD) |         |
|-----------------|---------|
| 20.6 (4.13)     | 22.4 (3.69) |
| <0.001          |         |

| Cancer stage, n (%) |         |
|---------------------|---------|
| I                   | 14 (11.7) |
| II                  | 63 (52.5) |
| II/III              | 3 (2.5)  |
| III                 | 28 (23.3) |
| IV                  | 12 (10.0) |
| 0.001               |         |

| Treatments, n (%) |         |
|-------------------|---------|
| Active surveillance| 8 (6.7) |
| Brachytherapy      | 37 (31.1) |
| RT                 | 13 (10.9) |
| RP                 | 22 (18.5) |
| RT + ADT (6 months)| 15 (12.6) |
| RT + ADT (24 months)* | 16 (13.8) |
| ADT (incident disease) | 4 (3.4) |
| ADT + chemotheraphy | 1 (0.8)  |
| ADT (24 months)*   | 6 (5.0)  |
| ADT + palliative ADT | 0 (0.0)  |
| RT + palliative ADT | 2 (1.7)  |
| RP + ADT           | 0 (0.0)  |
| 0.006              |         |

*Participants were proposed for 24 months of ADT and were still on ADT at the 1-year evaluation.*
administration of goserelin, to prevent testosterone flare. In these cases, the baseline evaluation was performed approximately 3 weeks after initiating antiandrogen but before the first goserelin administration. Docetaxel was used for chemotherapy.

**Statistical analysis**

Patients’ characteristics are described using counts and percentages, means and SD, or medians and P25 and P75. Based on the mean and SD of age- and education-specific norms,20 MoCA z-scores and t-scores were computed based on the formula \((z\text{-score} \times 10) + 50\), to obtain a more intelligible score, so that most values are positive and vary from 0 to 100.

Variation in cognitive performance was computed as the difference between MoCA at 1 year and at baseline. Participants with a variation below 1.5 SD of the distribution of changes in the cohort were considered to have cognitive decline.

Participants were considered to have cognitive impairment when scoring in the MoCA, below age- and education-normative reference values (1.5 SD below the mean). Among participants with no cognitive impairment at baseline, those presenting cognitive impairment at the 1-year evaluation were considered to have incident cognitive impairment.

The incidence of cognitive impairment and cognitive decline was compared between the ADT group and the non-ADT group using multivariate logistic regression to estimate odds ratios (ORs) and the corresponding 95% confidence intervals (95% CIs). The ADT group included patients treated with ADT only, those treated with radiotherapy (with or without brachytherapy) and ADT, those treated with ADT and chemotherapy, and those with persistent disease after radical prostatectomy or radiotherapy, treated with ADT. Stratified analyses were conducted according to the moment of the 1-year follow-up, and interaction terms computed: before versus after the onset of the pandemic.

**RESULTS**

Participants with the 1-year evaluation performed after the pandemic onset were more educated (55.7% versus 50.6% had >5 years of education, \(P = 0.016\)) but were similar in age and lifestyles. Nearly half never smoked and were practicing the recommended amount of physical activity, nearly 30% had a body mass index <25 kg/m², and half had hypertension (Table 2).

Mean MoCA scores increased from baseline to the 1-year evaluation [mean (SD): 22.3 (3.7) versus 22.8 (3.8), respectively; \(P < 0.001\)], but this variation, when the 1-year evaluation was performed after the onset of COVID-19 pandemic, was not statistically significant.

Table 3 presents the mean difference in MoCA t-scores from baseline to the 1-year evaluation according to prostate cancer treatment. Only the group treated with ADT and chemotherapy, and those who underwent radical prostatectomy (without adjuvant radiotherapy) had a statistically significant increase in mean t-scores over time [mean difference of MoCA t-score at 1 year minus MoCA t-score at baseline (95% CI): 7.59 (0.52-14.67) and 3.73 (1.10-6.37), respectively]. Patients treated with ADT only had a nonstatistically significant decrease and the remaining treatment groups had nonstatistically significant increases. The increase in scores was less pronounced after the COVID-19 pandemic.

At baseline, 47 participants had cognitive impairment and of these, 51.6% scored within the normal MoCA range. None of the patients treated with prostatectomy or with radiotherapy only had cognitive decline. Participants with ADT as part of their treatments presented cognitive decline more often (range 7.8%-16.0%). There were 22 incident cases of cognitive impairment corresponding to a 1-year cumulative incidence of cognitive impairment of 6.9% (95% CI 4.3%-10.2%), which was higher after the COVID-19 pandemic (9.1% versus 3.7%; \(P = 0.057\)). Patients who received

| Timing of the 1-year evaluation | \(P\) value |
|---------------------------------|------------|
| Before the COVID-19 pandemic | After the COVID-19 pandemic |

| Age | All | Before the COVID-19 pandemic | After the COVID-19 pandemic |
|-----|-----|-----------------------------|-----------------------------|
| \(\geq 68\) years (median) | 173 (47.3) | 71 (48.3) | 102 (46.6) |
| \(< 68\) years (median) | 185 (50.6) | 63 (42.9) | 122 (55.7) |

| Smoking status | \(n\) (%) | \(n\) (%) | \(n\) (%) |
|----------------|----------|----------|----------|
| Never smoker | 158 (44.1) | 62 (43.4) | 96 (44.7) |
| Ex-smoker | 164 (45.8) | 63 (44.1) | 101 (47.0) |
| Current smoker | 21 (5.7) | 10 (7.2) | 11 (5.0) |

| Excessive alcohol consumption | \(n\) (%) | \(n\) (%) | \(n\) (%) |
|-------------------------------|----------|----------|----------|
| Recommended physical activity | 159 (43.4) | 64 (43.5) | 95 (43.4) |

| Body mass index (kg/m²) | \(n\) (%) | \(n\) (%) |
|-------------------------|----------|----------|
| \(< 18.5\) | 1 (0.3) | 0 (0.0) |
| 18.5-24.0 | 81 (26.9) | 45 (33.6) |
| 25.0-29.9 | 154 (51.2) | 62 (46.3) |
| \(\geq 30\) | 65 (21.6) | 27 (20.1) |

| Comorbidities | \(n\) (%) | \(n\) (%) | \(n\) (%) |
|---------------|----------|----------|----------|
| Hypertension | 184 (50.3) | 75 (51.0) | 109 (49.8) |
| Heart disease | 66 (18.0) | 24 (16.3) | 42 (19.2) |
| Stroke | 12 (3.3) | 4 (2.7) | 8 (3.7) |
| Diabetes | 68 (18.6) | 26 (17.7) | 42 (19.2) |
| Lung disease | 35 (9.6) | 10 (6.8) | 25 (11.4) |
| Psychiatric disorder | 21 (5.7) | 6 (4.1) | 15 (6.8) |
| Nervous system disorder | 8 (2.2) | 1 (0.7) | 7 (3.2) |

COVID-19, coronavirus disease 2019.

\(^{a}\)At least 150 minutes of physical activity weekly (minutes of moderate physical activity + 2 × minutes of vigorous physical activity).

\(^{b}\)20-49 g/day for men aged 18-64 years and \(\geq 50\) g/day for men aged \(\geq 65\).
Table 3. Mean difference in the MoCA t-scores, according to cancer treatments (t-score at 1 year minus t-score at baseline)

| Treatments                          | All                          | Moment of the 1-year evaluation |
|-------------------------------------|------------------------------|---------------------------------|
|                                     | N Difference in MoCA t-scores, mean (95% CI) | N Difference in MoCA t-scores, mean (95% CI) | N Difference in MoCA t-scores, mean (95% CI) |
|                                     | Before COVID-19              | After COVID-19                   | After COVID-19                   |
| Active surveillance                 | 18                           | 1                              | 17                              | 1.682 (−2.279 to 5.643) |
| Brachytherapy                       | 52                           | 22                             | 30                             | 0.581 (−3.847 to 5.008) |
| RT                                  | 38                           | 12                             | 26                             | 0.698 (−3.020 to 4.415) |
| RP                                  | 59                           | 25                             | 34                             | 3.379 (−0.454 to 7.212) |
| RT + ADT 6 months                   | 35                           | 8                              | 27                             | 0.857 (−3.449 to 5.164) |
| RT + ADT 24 months                  | 90                           | 42                             | 48                             | 0.195 (−3.034 to 2.643) |
| ADT, incident PCa                   | 22                           | 12                             | 10                             | −1.971 (−10.778 to 6.836) |
| ADT + chemotherapy                  | 12                           | 5                              | 7                              | 7.549 (−5.442 to 20.540) |
| ADT, recurrent PCa                  | 25                           | 13                             | 12                             | −0.364 (−7.873 to 7.145) |
| RT + palliative ADT                 | 10                           | 0                              | 1                              | 10.490 |
| RP + RT                             | 13                           | 6                              | 7                              | 2.622 (−6.854 to 12.099) |
| RP + ADT                            | 1                            | 1                              | 0                              | −1.748 |
| Total                               | 366                          | 147                            | 219                            | 1.143 (−0.260 to 2.547) |

Results in bold correspond to statistically significant variations.

ADT, androgen-deprivation therapy; CI, confidence interval; COVID-19, coronavirus disease 2019; MoCA, Montreal Cognitive Assessment; PCa, prostate cancer; RP, radical prostatectomy; RT, radiotherapy; SD, standard deviation.

*aParticipants were proposed for 24 months of ADT and were still on ADT at the 1-year evaluation.

Table 4. Cognitive outcomes at 1 year, according to prostate cancer treatment, before and after the COVID-19 pandemic

| Treatments                          | Cognitive decline | Incident cognitive impairment |
|-------------------------------------|------------------|------------------------------|
|                                     | All              | Incident of the 1-year evaluation |
|                                     | N n (%)          | Before COVID-19               | After COVID-19               |
|                                     | N n (%)          | N at risk n (%)               | N at risk n (%)               |
|                                     | N n (%)          | N at risk n (%)               | N at risk n (%)               |
| Active surveillance                 | 18               | 1 (5.6)                       | 17 (0.0)                     | 0 (0.0)                       |
| Brachytherapy                       | 52               | 22 (4.5)                      | 30 (6.7)                     | 45 (2.2)                      |
| RT                                  | 38               | 12 (0.0)                      | 26 (0.0)                     | 34 (0.0)                      |
| RP                                  | 59               | 25 (0.0)                      | 34 (0.0)                     | 48 (3.6)                      |
| RT + ADT 6 months                   | 35               | 8 (12.5)                      | 27 (2.7)                     | 28 (2.7)                      |
| RT + ADT 24 months                  | 90               | 42 (2.4)                      | 48 (12.5)                    | 84 (11.3)                     |
| ADT, incident PCa                   | 22               | 12 (8.3)                      | 10 (2.0)                     | 20 (1.0)                      |
| ADT + chemotherapy                  | 12               | 0 (0.0)                       | 7 (14.3)                     | 10 (0.0)                      |
| ADT, recurrent PCa                  | 25               | 13 (23.1)                     | 12 (8.3)                     | 22 (1.4)                      |
| RT + palliative ADT                 | 1                | 0 (0.0)                       | 1 (0.0)                      | 1 (0.0)                       |
| RP + RT                             | 13               | 6 (16.7)                      | 7 (0.0)                      | 13 (2.8)                      |
| RP + ADT                            | 1                | 1 (100.0)                     | 0 (0.0)                      | 1 (0.0)                       |
| Total                               | 366              | 147 (4.6)                     | 219 (10.6)                   | 321 (22.6)                    |

Differences between treatments: age (P < 0.001), education (P < 0.004), cognitive decline (P = 0.004), incident cognitive impairment (P = 0.285).

ADT, androgen-deprivation therapy; COVID-19, coronavirus disease 2019; PCa, prostate cancer; RP, radical prostatectomy; RT, radiotherapy.

*aParticipants were proposed for 24 months of ADT and were still on ADT at the 1-year evaluation.

radiotherapy as an adjuvant treatment after radical prostatectomy had the highest 1-year cumulative incidence of cognitive impairment (15.4%), followed by those treated with radiotherapy combined with long-duration ADT (13.1%), and those treated with ADT for incident prostate cancer only (10.0%). None of the patients who received ADT and chemotherapy had incident cognitive impairment at 1 year.

A higher educational level (>12 years) was associated with cognitive decline [age-adjusted OR (95% CI): 2.89 (1.12-7.46)]. Patients who underwent treatments including ADT had higher odds of cognitive decline compared with patients who were not treated with ADT [age and education aOR (95% CI): 3.71 (1.31-10.59)]. The moment of the 1-year assessment (before/after COVID-19) was not significantly associated with cognitive decline [aOR (95% CI): 0.95 (1.41-32.87)] and the interaction with ADT-based treatments was not statistically significant (P = 0.233), but the association between the COVID-19 pandemic and incident cognitive impairment was nearly statistically significant [aOR (95% CI): 2.65 (0.95-7.23)] and its interaction with ADT-based treatments was significant (P = 0.044). The association between ADT and incident cognitive impairment was only statistically significant after the pandemic [aOR (95% CI): 5.53 (1.46-20.95)]. Anxiety and depression symptoms were not associated with cognitive decline or incident cognitive impairment (Figure 1).

4 https://doi.org/10.1016/j.esmoop.2022.100448 Volume 7 ■ Issue 2 ■ 2022
DISCUSSION

Overall, cognitive performance increased from baseline to the 1-year evaluation. Patients treated with ADT were more likely to have cognitive decline after 1 year of follow-up. The incidence of cognitive impairment was almost 7% and it was higher in patients treated with ADT, alone or with other treatments, but this effect was only observed when the 1-year assessment was conducted after the COVID-19 pandemic.

In the current study, mean MoCA scores increased over time, which was also observed in women with breast cancer during the first year after cancer diagnosis. This increase may reflect a practice effect, that is, an improvement due to becoming familiar with the testing procedures and the cognitive tasks but also due to a lower performance at baseline because of the overwhelming experience of a cancer diagnosis, and fear of treatments and prognosis, that may have dissipated after 1 year. Indeed, in the present study, borderline anxiety (a score ≥8 in the anxiety subscore of the HADS) was associated with MoCA scores at baseline, and patients proposed for radical prostatectomy had the lowest mean MoCA scores and the highest prevalence of borderline anxiety. However, this may not explain the low baseline MoCA scores in patients proposed for ADT and chemotherapy, as the prevalence of borderline anxiety was low in this group. Pain associated with bone metastases could explain the lower cognitive performance at baseline, although this assessment was usually performed after 3 weeks of antiandrogens for pain management and flare prevention. Pathological alterations due to cancer and the control of the disease after 1 year may explain low cognitive performance at baseline and improvement thereafter, respectively.

Cognitive decline, defined as having a variation in MoCA scores over time <1.5 SD of the variation in the cohort, was consistently more frequent in participants treated with ADT, regardless of the duration of ADT or associated treatments, and the incident or recurrent nature of the disease.

| Category                      | OR (95% CI) adj | adj |
|-------------------------------|----------------|-----|
| Age (years; ref. <65)         |                |     |
| ≥65                           | 1.60 (0.58-4.39) |     |
| Education (years; ref. ≤12)   |                |     |
| >12                           | 2.89 (1.12-7.46) | a   |
| Anxiety                       |                |     |
| At baseline                   | 0.55 (0.07-4.26) |     |
| At 1 year                     | 1.22 (0.27-5.53) |     |
| Depression                    |                |     |
| At baseline                   | - Not applicable | b   |
| At 1 year                     | 1.21 (0.27-5.47) |     |
| Cancer stage (ref. Stage I)   |                |     |
| Stage II                      | 0.50 (0.09-2.72) | c   |
| Stage III                     | 0.53 (0.09-2.94) | c   |
| Stage IV                      | 1.22 (0.23-6.42) | c   |
| COVID-19 pandemic             |                |     |
| yes versus no                 | 0.95 (0.41-2.21) | c   |
| ADT versus no ADT             |                |     |
| Anytime                       | 3.71 (1.31-10.59) | c   |
| pre-COVID-19                  | 1.93 (0.46-8.14) | c   |
| post-COVID-19                 | 6.81 (1.41-32.87) | c   |

Figure 1. Association of age, education, anxiety, and depression, and treatments with cognitive decline and with incident cognitive impairment.

95% CI, 95% confidence interval; ADT, androgen-deprivation therapy; CD, cognitive decline defined as a variation in cognitive performance [Montreal Cognitive Assessment (MoCA) at 1 year minus MoCA at baseline] below 1.5 standard deviations of the variation in the whole cohort; COVID-19, coronavirus disease 2019; incCI, incident cognitive impairment defined as a score below age- and education-specific values from normative data at the 1-year evaluation in participants without cognitive impairment at baseline.

aAdjusted for age.
bNone of the participants had the outcome (cognitive decline/incident cognitive impairment).
cAdjusted for age and education.
result supports the evidence from previous studies reporting an association of ADT with cognitive decline. In cross-sectional evaluations, a higher educational level has been associated with better cognitive performance. However, similar or higher rate of decline in some cognitive domains were reported in older adults with higher versus lower education. Moreover, among patients with incident Alzheimer’s disease, a more accelerated cognitive decline was reported in individuals with higher education. In the present study, patients with >12 years of education were more likely to belong to the group with the worst variation in cognitive scores over 1 year of follow-up, but no association with incident cognitive impairment was observed.

Most of the cases with cognitive decline (13/22) had high baseline MoCA score, which decreased at least 4 points, while remaining within the normal range for the specific age and education group. By contrast, most cases of incident cognitive impairment (also 13/22) had a decrease in MoCA scores between 1 and 3 points. Future assessments of the participants, as well as confirmation of cognitive impairment, with a battery of neuropsychological tests and a neurologist diagnosis are needed to refine these results, considering, in one hand, that a very high or low score at baseline or at 1 year may be due to chance only, being the variation observed a result of the phenomenon of regression to the mean, and, in the other hand, that the MoCA is a screening test.

In another longitudinal study of cognitive performance over a 5-year period in patients with breast cancer, the variation in MoCA scores in the first year of follow-up was a significant predictor of long-term cognitive decline. Although population- and cancer-specific differences may not allow to extrapolate the findings to the present study, the incidence of cognitive impairment at 1 year was similar to that observed among women with breast cancer 1 year after cancer diagnosis and using the MoCA (8.1%). These are two different populations of patients with cancer, regarding not only sex but also age and treatments. To our knowledge, there are no studies reporting the incidence of cognitive impairment in patients with prostate cancer. Patients treated with ADT were more likely to develop cognitive impairment, a consistent observation considering ADT alone or with radiotherapy, although none of the participants treated with ADT and chemotherapy had incident cognitive impairment. Patients proposed for chemotherapy were younger than those with ADT, which could explain this difference in the cognitive impairment incidence, as well as unmeasured factors related to overall health and lifestyle. In addition, docetaxel may not have deleterious effects in cognitive function as other drugs or combinations of drugs used in other cancers. Finally, this null result should be interpreted considering that there was a small number of patients treated with this drug, precluding a definitive conclusion on the effect of docetaxel on cognitive function.

The first COVID-19 case in Portugal was reported on 2 March 2020, and the NEON-PC cohort evaluations were suspended from 9 March to 1 July 2020. The first general lockdown occurred from 22 March to 30 April 2020 and the second between 16 January and 15 March 2021, during which the general population was forbidden from using public spaces, and compulsory confinement was legally imposed, except for basic shopping necessities, health consultations and treatments, and going to work when working from home was not possible. Total confinement and restrictions to normal daily activities since March 2020 have caused many alterations in everyone’s life, with a decrease in physical activity and an increase in sedentary behaviours, and changes in eating patterns. Moreover, the reduction in contact with nature was associated with worse mental health, and sleep problems were frequent during the COVID-19 pandemic. ADT has been associated with a higher risk for weight gain and metabolic syndrome, depression, and sleep disturbances. These adverse effects of ADT are associated with cognitive dysfunction, acting as potential mediators of the effect of ADT on cognitive performance. We observed a negative effect of ADT on the incidence of cognitive impairment, but only after the COVID-19 pandemic, which may be explained by a worsening effect of the pandemic in the prevalence of metabolic syndrome, depression, and sleep problems among patients who received ADT.

Strengths and limitations
This is the largest prospective study comparing cognitive decline in patients with prostate cancer treated with or without ADT, and the first to report cognitive impairment cumulative incidence in these patients. Although neuropsychological tests are considered the gold standard to assess cognitive performance, which and how many tests to include to assess which cognitive domains, and the criteria to define cognitive impairment have not yet been standardized. Moreover, neuropsychological assessment may not be feasible both in clinical practice and in research. Indeed, due to the long duration for the administration of the battery of tests (at least one hour), the availability of neuropsychologists to administer and score the tests, and the willingness of participants to perform such long sessions may compromise the execution of comprehensive neuropsychological evaluations. Even while using a cognitive test that may not detect subtle changes in cognitive performance, our results show that ADT is associated with the deterioration of overall cognitive function.

The 1-year follow-up may not have been sufficient to detect the association of ADT with incident cognitive impairment in patients with the two evaluations performed before the COVID-19 pandemic, and future evaluations of the cohort may detect the effect of cumulative exposure to this therapy. Although this study was conducted in only one hospital, IPO-Porto receives patients from all over the country, though mostly from the North, and it is the largest cancer-dedicated public hospital in Portugal.

Conclusion
Patients with prostate cancer treated with ADT are more likely to have a deterioration in cognitive performance.
year after initiating treatment. Therefore cognitive assessment should be considered in the clinical follow-up protocols of these patients. Socioeconomic, lifestyle, and clinical characteristics should also be considered in-depth to identify the moderators of the association of ADT with cognitive performance, and studies with longer follow-up are needed to understand if the negative effect of ADT is reversible after treatment termination. The COVID-19 pandemic may have worsened the effect of ADT in the cognitive performance of patients with prostate cancer.

**FUNDING**

This study was funded by the European Regional Development Fund through the Operational Programme Competitiveness and Internationalisation, and national funding from the Fundação para a Ciência e a Tecnologia - FCT (Portuguese Ministry of Science, Technology and Higher Education) under the project ‘NEON-PC - Neuro-oncological complications of prostate cancer: longitudinal study of cognitive decline’ (POCI-01-0145-FEDER-032358; Ref. PTDC/SAU-EPI/32358/2017), and the Unidade de Investigação em Epidemiologia - Instituto de Saúde Pública da Universidade do Porto (EPIUnit; UIDB/04750/2020) and Laboratório para a Investigação Integrativa e Transicional em Saúde Populacional (LA/P/0064/2020), financed by national funds from FCT. AC and SM were funded under the scope of the ‘Programa Operacional Capital Humano’ (POCH/FSE).

**DISCLOSURE**

The authors have no relevant financial or nonfinancial interests to disclose.

**DATA SHARING**

The datasets generated and analysed in this study will not be publicly available given that the included patients do not specifically provide their consent for public sharing of their data and that anonymization is unlikely to be feasible, because the identification of patients treated in only one institution within a relatively short period may be possible when taking sociodemographic and clinical characteristics into account.

**ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

Ethics approval was obtained from the Ethics Committee of the Portuguese Institute of Oncology of Porto (Ref. CES 89/017) and by the Portuguese Data Protection Authority (Authorisation 3478/2017). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all participants after the project’s aims and procedures had been fully explained by a member of the research team.

**CONSENT FOR PUBLICATION**

Not applicable.

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615-1624.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline). Prostate Cancer. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2020.
4. McGinty HL, Phillips KM, Jim HS, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22(8):2271-2280.
5. Kim JH, Lee B, Han DH, Chung KJ, Jeong IG, Chung BI. Discrepancies on the association between androgen deprivation therapy for prostate cancer and subsequent dementia: meta-analysis and meta-regression. Oncotarget. 2017;8(42):73087-73097.
6. Lee HH, Park S, Joung JY, Kim SH. How does androgen deprivation therapy affect mental health including cognitive dysfunction in patients with prostate cancer? World J Mens Health. 2021;38:598-605.
7. Khosrow-Khavar F, Rej S, Yin H, Aprikian A, Azoulay L. Androgen deprivation therapy and the risk of dementia in patients with prostate cancer. J Clin Oncol. 2017;35(2):201-207.
8. Hong J-H, Huang C-Y, Chang C-H, et al. Different androgen deprivation therapies might have a different impact on cognition - an analysis from a population-based study using time-dependent exposure model. Cancer Epidemiol. 2020;64:101657.
9. Sari Motlagh R, Quhal F, Mori K, et al. The risk of new onset dementia and/or Alzheimer disease among patients with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2021;205(1):60-67.
10. Ryan C, Wefel JS, Morgans AK. A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer Prostatic Dis. 2020;23(2):207-219.
11. Treanor CJ, Li J, Donnelly M. Cognitive impairment among prostate cancer patients: an overview of reviews. Eur J Cancer Care. 2017;26(6). https://doi.org/10.1111/ecc.12642.
12. Figuracion KCF, Lewis FM. Environmental enrichment: a concept analysis. Nursing Forum. 2021;56(3):703-709.
13. Barguilla A, Fernández-Lebrero A, Estragués-Gázquez I, et al. Effects of COVID-19 pandemic confinement in patients with cognitive impairment. Front Neurol. 2020;11:589901-589901.
14. Araujo N, Morais S, Costa AR, et al. Cognitive decline in patients with prostate cancer: study protocol of a prospective cohort, NEON-PC. BMJ Open. 2021;11(2):e043844.
15. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
16. Pais-Ribeiro J, Silva I, Ferreira T, Martins A, Meneses R, Baltar M. Validation study of a Portuguese version of the Hospital Anxiety and Depression Scale. Psychol Health Med. 2007;12(2):225-235.
17. Zigmond AS, Snith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361-370.
18. Amin MB, Edge SB. AJCC Cancer Staging Manual. Berlin, Germany: Springer; 2017.
19. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244-252.
20. Freitas S, Simões MR, Alves L, Santana I. Montreal Cognitive Assessment (MoCA): normative study for the Portuguese population. J Clin Exp Neuropsychol. 2011;33(9):989-996.
21. Freitas S, Simões M, Martins C, Vilar M, Santana I. Adaptation studies of the Montreal Cognitive Assessment (MoCA) to the Portuguese population. Aval Psicol. 2010;9(3):345-357.
22. Araújo N, Severo M, Lopes-Conceição L, et al. Trajectories of cognitive performance over five years in a prospective cohort of patients with breast cancer (NEON-BC). Breast. 2021;58:130-137.
23. Korfage IJ, Essink-Bot ML, Janssens ACJW, Schröder FH, de Koning HJ. Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer. 2006;94(8):1093-1098.
24. Ritchie K. Mild cognitive impairment: an epidemiological perspective. Dialogues Clin Neurosci. 2004;6(4):401.
25. Wilson RS, Hebert LE, Scherr PA, Barnes LL, Mendes de Leon CF, Evans DA. Educational attainment and cognitive decline in old age. Neurology. 2009;72(5):460-465.
26. Scarmeas N, Albert SM, Manly JJ, Stern Y. Education and rates of cognitive decline in incident Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2006;77(3):308-316.
27. Ramalho M, Fontes F, Ruano L, Pereira S, Lunt N. Cognitive impairment in the first year after breast cancer diagnosis: a prospective cohort study. Breast. 2017;32:173-178.
28. República Portuguesa. Não paramos - Estamos on: Resposta de Portugal à COVID-19 [We don’t stop - We are on: Portugal’s response to COVID-19]. Available at https://covid19estamoson.gov.pt/. Accessed July 6, 2021.
29. Stockwell S, Trott M, Tully M, et al. Changes in physical activity and sedentary behaviours from before to during the COVID-19 pandemic lockdown: a systematic review. BMJ Open Sport Exerc Med. 2021;7(1):e000960.
30. Ramalho SM, Trovisqueira A, de Lourdes M, et al. The impact of COVID-19 lockdown on disordered eating behaviors: the mediation role of psychological distress. Eat Weight Disord. 2022;27:179-188.
31. Ribeiro AI, Triguero-Mas M, Jardim Santos C, et al. Exposure to nature and mental health outcomes during COVID-19 lockdown. A comparison between Portugal and Spain. Environ Int. 2021;154:106664.
32. Jahrami H, BAHamamam AS, Bragazzi NL, Saif Z, Faris M, Vitiello MV. Sleep problems during the COVID-19 pandemic by population: a systematic review and meta-analysis. J Clin Sleep Med. 2021;17(2):299-313.
33. Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijk M. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PloS One. 2015;10(3):e0117344.
34. Nead KT, Sinha S, Yang DD, Nguyen PL. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: a systematic review and meta-analysis. Urol Oncol. 2017;35(11):664.e1-664.e9.
35. Gonzalez BD, Small BJ, Cases MG, et al. Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: the role of hot flashes and nocturia. Cancer. 2018;124(3):499-506.
36. Yates KS, Sweat V, Yau PL, Turchiano MM, Convit A. Impact of metabolic syndrome on cognition and brain: a selected review of the literature. Arterioscler Thromb Vasc Biol. 2012;32(9):2060-2067.
37. Yaffe K. Metabolic syndrome and cognitive decline. Curr Alzheimer Res. 2007;4(2):123-126.
38. Kim B, Feldman EL. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med. 2015;47:e149.
39. Sachs-Ericsson N, Joiner T, Plant EA, Blazer DG. The influence of depression on cognitive decline in community-dwelling elderly persons. Am J Geriatr Psychiatry. 2005;13(5):402-408.
40. Yaffe K, Falvey C, Hoang T. Connections between sleep and cognition in older adults. Lancet Neurol. 2014;13(10):1017-1028.
41. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703-708.